Tricaprylin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Tricaprylin
DrugBank Accession Number
DB12176
Background

Tricaprilin has been used in trials studying the supportive care and treatment of Alzheimer's Disease.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 470.6823
Monoisotopic: 470.360739332
Chemical Formula
C27H50O6
Synonyms
  • Caprylic acid triglyceride
  • Caprylic triglyceride
  • Glycerol tricaprylate
  • Glycerol trioctanoate
  • Tricaprilin
  • Tricaprylyl glycerin
  • Tricaprylyl glycerol
External IDs
  • AC-1202
  • AC-1204
  • Miglyol 808

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as triacylglycerols. These are glycerides consisting of three fatty acid chains covalently bonded to a glycerol molecule through ester linkages.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Glycerolipids
Sub Class
Triradylcglycerols
Direct Parent
Triacylglycerols
Alternative Parents
Tricarboxylic acids and derivatives / Fatty acid esters / Carboxylic acid esters / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Aliphatic acyclic compound / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester / Fatty acid ester / Fatty acyl / Hydrocarbon derivative / Organic oxide / Organic oxygen compound / Organooxygen compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
octanoate ester, triglyceride (CHEBI:76978) / Triacylglycerols (C13044)
Affected organisms
Not Available

Chemical Identifiers

UNII
6P92858988
CAS number
538-23-8
InChI Key
VLPFTAMPNXLGLX-UHFFFAOYSA-N
InChI
InChI=1S/C27H50O6/c1-4-7-10-13-16-19-25(28)31-22-24(33-27(30)21-18-15-12-9-6-3)23-32-26(29)20-17-14-11-8-5-2/h24H,4-23H2,1-3H3
IUPAC Name
1,3-bis(octanoyloxy)propan-2-yl octanoate
SMILES
[H]C(COC(=O)CCCCCCC)(COC(=O)CCCCCCC)OC(=O)CCCCCCC

References

General References
Not Available
Human Metabolome Database
HMDB0011187
PubChem Compound
10850
PubChem Substance
347828463
ChemSpider
10393
RxNav
1314420
ChEBI
76978
ChEMBL
CHEMBL1406148
ZINC
ZINC000008214697
Wikipedia
Axona

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Not Yet RecruitingTreatmentAlzheimer's Disease (AD)1
2Active Not RecruitingPreventionMigraine1
2CompletedTreatmentAge-Associated Memory Impairment (AAMI)1
2CompletedTreatmentAlzheimer's Disease (AD)1
2, 3CompletedSupportive CareAlzheimer's Disease (AD)1
2, 3WithdrawnTreatmentAlzheimer's Disease (AD)1
1CompletedNot AvailableHealthy Subjects (HS)1
1CompletedBasic ScienceAlzheimer's Disease (AD)3
1CompletedOtherHealthy Subjects (HS)3
1CompletedOtherTaste Profile Assessments1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility6.36e-05 mg/mLALOGPS
logP7.41ALOGPS
logP8.25ChemAxon
logS-6.9ALOGPS
pKa (Strongest Basic)-6.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area78.9 Å2ChemAxon
Rotatable Bond Count26ChemAxon
Refractivity130.87 m3·mol-1ChemAxon
Polarizability57.31 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 20, 2016 21:32 / Updated on June 12, 2020 16:53